Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atreca (BCEL – Research Report), Lucid Diagnostics (LUCD – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report).
Atreca (BCEL)
Canaccord Genuity analyst John Newman maintained a Buy rating on Atreca today and set a price target of $2.00. The company’s shares closed last Tuesday at $0.26, close to its 52-week low of $0.20.
According to TipRanks.com, Newman is a 5-star analyst with an average return of
Currently, the analyst consensus on Atreca is a Moderate Buy with an average price target of $2.00, a 746.7% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Lucid Diagnostics (LUCD)
In a report released yesterday, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Lucid Diagnostics, with a price target of $3.00. The company’s shares closed last Tuesday at $1.30.
According to TipRanks.com, CFA is ranked 0 out of 5 stars with an average return of
Lucid Diagnostics has an analyst consensus of Strong Buy, with a price target consensus of $4.58, a 324.1% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $2.50 price target.
Vertex Pharmaceuticals (VRTX)
Canaccord Genuity analyst Whitney Ijem maintained a Hold rating on Vertex Pharmaceuticals yesterday and set a price target of $336.00. The company’s shares closed last Tuesday at $369.95, close to its 52-week high of $387.42.
According to TipRanks.com, Ijem is a 5-star analyst with an average return of
Currently, the analyst consensus on Vertex Pharmaceuticals is a Moderate Buy with an average price target of $392.58, representing a 3.1% upside. In a report issued on November 7, RBC Capital also maintained a Hold rating on the stock with a $347.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BCEL:
- Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
- BCEL Upcoming Earnings Report: What to Expect?
- Atreca announces departure of CFO Cross, agreement to terminate lease
- Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
